XML 110 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Revenues:            
Clinical treatment programs – US $ 35 $ 46 $ 125 $ 137 $ 202 $ 141
Total Revenues 35 46 125 137 202 141
Costs and Expenses:            
Production costs 8 30 24 30 42
Research and development 1,437 2,734 4,533 7,739 10,939 6,990
General and administrative 3,079 5,439 9,485 10,280 21,137 13,074
Total Costs and Expenses 4,524 8,203 14,042 18,049 32,118 20,064
Operating loss (4,489) (8,157) (13,917) (17,912) (31,916) (19,923)
Gain (loss) on investments 273 (310) 96 (201) 200 (1,679)
Interest and other income 718 294 3,379 811 1,069 629
Interest expense and other finance costs (202) (453)    
Gain on sale of fixed assets 39 16 18 3
Redeemable warrants valuation adjustment         35
(Loss) on warrant issuance (458)    
Gain from sale of income tax operating losses 318 900 1,667 1,490
Net Loss $ (3,700) $ (7,816) $ (11,353) $ (16,386) $ (28,962) $ (19,445)
Basic loss per share $ (0.06) $ (0.16) $ (0.21) $ (0.34) $ (0.60) $ (0.40)
Diluted loss per share $ (0.06) $ (0.16) $ (0.21) $ (0.34) $ (0.60) $ (0.40)
Weighted average shares outstanding basic 57,677,016 48,635,165 53,351,467 48,483,802 48,585,404 48,047,288
Weighted average shares outstanding diluted 57,677,016 48,635,165 53,351,467 48,483,802 48,585,404 48,047,288